Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-Assisted Therapy for Veterans With PTSD and Moral Injury
NCT06394284Phase 3Recruiting
- Sponsor
- Herzog Hospital
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midomafetamine in post-traumatic stress disorder (PTSD) and moral injury (2 arms), sponsored by Herzog Hospital. Primary endpoints: Post-Traumatic Stress Disorder Symptom Severity at 4 months and Oxytocin Levels at 3 months. Started May 2024; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)moral injury
Beyond the preview
Go deeper on NCT06394284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394284.